Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Hormone Refractory Prostate Cancer Market Forecast: What Market Value Is Expected By 2030?
The global market for hormone-refractory prostate cancer experienced considerable expansion, projected to increase from its 2025 valuation of $8.12 billion to $8.95 billion by 2026, reflecting a compound annual growth rate of 10.2%. This upward trajectory during the historical period was fueled by several key factors, including an escalating prevalence of advanced prostate cancer cases, the broad acceptance and application of androgen deprivation therapy, augmented access to pharmaceutical agents for chemotherapy, a greater reliance on PSA-level testing for disease surveillance, and the continuous development of healthcare systems focused on oncology.
The market for hormone refractory prostate cancer is poised for substantial expansion over the upcoming years, projecting a reach of $13.09 billion by 2030, driven by a compound annual growth rate of 10.0%. This anticipated growth trajectory is underpinned by several key factors, including advancements in the development of targeted therapeutic agents, an uptick in clinical investigations concerning castration-resistant prostate cancer, an escalating demand for customized oncological care, the broadening scope of immuno-oncology research and development, and increased investment in cancer treatment modalities. Key developments anticipated during this forecast period encompass a greater embrace of precision oncology treatments, a rise in the utilization of combined pharmaceutical interventions, a more prevalent application of biomarker-guided treatment selection, an expanded role for immunotherapies in managing advanced stages of prostate cancer, and a heightened emphasis on individualizing treatment plans.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25786&type=smp
Hormone Refractory Prostate Cancer Market Growth Factors: Which Forces Are Supporting Market Expansion?
Increased financial backing for cancer investigations is anticipated to spur the expansion of the hormone-refractory prostate cancer sector. This surge in funding supports the development of novel strategies for identifying, managing, and preventing cancer, prompted by the escalating worldwide incidence of the disease. Such investment fuels advancements in treating hormone-refractory prostate cancer, facilitating the adoption of sophisticated interventions like radioligand therapies and hormonal blockers, while also financing crucial clinical trials and biomarker studies to refine treatment accuracy and improve patient results. As an illustration, the Cancer Research Institute, a non-profit focused on immunotherapy, allocated approximately $22.8 million in its 2023–2024 fiscal period to support 64 new research grants across 42 institutions in seven nations. Consequently, the escalating commitment to cancer research is a key driver for the hormone-refractory prostate cancer market’s growth.
Hormone Refractory Prostate Cancer Market Segment Breakdown: Which Categories Generate The Most Revenue?
The hormone refractory prostate cancer market covered in this report is segmented –
1) By Treatment Type: Chemotherapy, Hormonal Therapy, Immunotherapy, Radiation Therapy, Surgery
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End-User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Other End-Users
Subsegments:
1) By Chemotherapy: Docetaxel, Cabazitaxel, Mitoxantrone, Estramustin
2) By Hormonal Therapy: Anti-Androgens, CYP17 Inhibitors, LHRH Agonists, LHRH Antagonists
3) By Immunotherapy: Cancer Vaccines, Immune Checkpoint Inhibitors, Adoptive Cell Therapy
4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Brachytherapy, Radionuclide Therapy
5) By Surgery: Radical Prostatectomy, Orchiectomy, Transurethral Resection Of The Prostate (TURP)
Hormone Refractory Prostate Cancer Market Industry Trends: What Changes Are Reshaping Demand?
Key players within the hormone-refractory prostate cancer sector are directing their efforts toward pioneering sophisticated treatments, notably intravenous radioligand therapy, with the aim of enhancing prognoses for individuals battling forms of the illness that no longer respond to conventional therapies. This innovative intravenous radioligand therapy approach functions as a precisely targeted intervention, employing radioactive compounds linked to carriers that specifically seek out and adhere to markers unique to cancer cells, thereby eradicating malignant cells from within while minimizing harm to adjacent healthy tissues. A significant development occurred in March 2025 when Novartis AG, a pharmaceutical entity headquartered in Switzerland, secured FDA approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan), a therapeutic agent intended for earlier application in patients diagnosed with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have previously undergone androgen receptor pathway inhibitor (ARPI) treatment and are candidates for delaying chemotherapy. This broadened approval, stemming from the pivotal Phase III PSMAfore study, substantially increases the pool of eligible patients by an estimated factor of three, demonstrating that Pluvicto achieved a 59% reduction in the risk of radiographic progression or mortality and more than doubled the median radiographic progression-free survival when contrasted with a switch to an alternative ARPI. Consequently, Pluvicto stands as the inaugural targeted radioligand therapy sanctioned for utilization prior to chemotherapy in this particular clinical context, presenting a novel therapeutic avenue that effectively postpones disease advancement alongside a well-tolerated safety profile.
Hormone Refractory Prostate Cancer Market Key Players And Strategic Industry Positioning
Major companies operating in the hormone refractory prostate cancer market are Pfizer Inc, Johnson And Johnson, F Hoffmann La Roche Ltd, Merck And Co Inc, AbbVie Inc, Bayer AG, Sanofi SA, Bristol Myers Squibb Company, Novartis AG, AstraZeneca Plc, Eli Lilly And Company, Amgen Inc, Astellas Pharma Inc, Ipsen Pharma, Exelixis Inc, Orion Corporation, Lantheus Holdings Inc, Clovis Oncology Inc, Telix Pharmaceuticals, Dendreon Pharmaceuticals LLC, Janssen Pharmaceuticals Inc, Bayer Healthcare Pharmaceuticals Inc
Access The Complete Hormone Refractory Prostate Cancer Market Report:
Hormone Refractory Prostate Cancer Market Global Footprint: Which Region Holds Market Leadership?
North Americawas the largest region in the hormone-refractory prostate cancer market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the hormone refractory prostate cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
